氟哌啶醇与安慰剂治疗急性入住ICU成人谵妄患者的长期结局比较
该研究为AID-ICU试验的预设1年结局分析,纳入1000例急性入住ICU的成人谵妄患者,比较氟哌啶醇与安慰剂的长期效果。1年随访获得96.2%患者的生命状态和83.3%患者的健康相关生活质量数据。氟哌啶醇组1年死亡224/501(44.7%),安慰剂组251/486(51.6%),调整绝对风险差-6.4个百分点(95%CI -12.8至-0.2,P=0.045)。健康相关生活质量方面,EQ-5D-5L指数值调整平均差0.04(95%CI -0.03至0.11,P=0.091),EQ VAS调整平均差3.3(95%CI -9.3至17.5,P=0.142),均无统计学显著差异。
要点
- 急性入住ICU的谵妄成人患者中,氟哌啶醇组1年死亡224/501(44.7%),安慰剂组251/486(51.6%),调整绝对风险差-6.4个百分点(95%CI -12.8至-0.2,P=0.045)。
- 氟哌啶醇组与安慰剂组的健康相关生活质量EQ-5D-5L指数值调整平均差0.04(95%CI -0.03至0.11,P=0.091),无统计学显著差异。
- EQ VAS调整平均差3.3(95%CI -9.3至17.5,P=0.142),氟哌啶醇组与安慰剂组无统计学显著差异。
- 1年随访获得96.2%患者的生命状态和83.3%患者的健康相关生活质量数据。
适用人群与场景
- 急性入住ICU的成人谵妄患者,来自AID-ICU试验随机化的1000例患者。
研究设计与关键结果
- 研究类型:AID-ICU试验的预设1年结局分析,纳入1000例急性入住ICU的成人谵妄患者。
- 干预与对照:氟哌啶醇与安慰剂比较。
- 主要终点:1年死亡率,氟哌啶醇组224/501(44.7%)vs 安慰剂组251/486(51.6%),调整绝对风险差-6.4个百分点(95%CI -12.8至-0.2,P=0.045)。
- 关键次要终点:EQ-5D-5L指数值调整平均差0.04(95%CI -0.03至0.11,P=0.091);EQ VAS调整平均差3.3(95%CI -9.3至17.5,P=0.142)。
- 随访数据完整性:获得96.2%患者的生命状态和83.3%患者的健康相关生活质量数据。
证据类型、等级与局限
- 证据类型:随机对照试验(AID-ICU)的预设1年结局分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在急性入住ICU的成人谵妄患者中,氟哌啶醇治疗与1年死亡率降低相关,但未统计学显著改善健康相关生活质量。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: We assessed long-term outcomes in acutely admitted adult patients with delirium treated in intensive care unit (ICU) with haloperidol versus placebo.
METHODS: We conducted pre-planned analyses of 1-year outcomes in the Agents Intervening against Delirium in the ICU (AID-ICU) trial, including mortality and health-related quality of life (HRQoL) assessed by Euroqol (EQ) 5-dimension 5-level questionnaire (EQ-5D-5L) index values and EQ visual analogue scale (EQ VAS) (deceased patients were assigned the numeric value zero). Outcomes were analysed using logistic and linear regressions with bootstrapping and G-computation, all with adjustment for the stratification variables (site and delirium motor subtype) and multiple imputations for missing HRQoL values.
RESULTS: At 1-year follow-up, we obtained vital status for 96.2% and HRQoL data for 83.3% of the 1000 randomised patients. One-year mortality was 224/501 (44.7%) in the haloperidol group versus 251/486 (51.6%) in the placebo group, with an adjusted absolute risk difference of - 6.4%-points (95% confidence interval [CI] - 12.8%-points to - 0.2%-points; P = 0.045). These results were largely consistent across the secondary analyses. For HRQoL, the adjusted mean differences were 0.04 (95% CI - 0.03 to 0.11; P = 0.091) for EQ-5D-5L-5L index values, and 3.3 (95% CI - 9.3 to 17.5; P = 0.142) for EQ VAS.
CONCLUSIONS: In acutely admitted adult ICU patients with delirium, haloperidol treatment reduced mortality at 1-year follow-up, but did not statistically significantly improve HRQoL.
参考来源
- Mortensen CB, Andersen-Ranberg NC, Poulsen LM, et al. Long-term outcomes with haloperidol versus placebo in acutely admitted adult ICU patients with delirium. Intensive Care Med. 2024. PMID: 38170227. doi:10.1007/s00134-023-07282-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。